Retrospective Review of Patients with Metastatic High Grade Neuroendocrine Carcinoma of the Pancreas: Memorial Sloan-Kettering Cancer Center Experience (MSKCC) [Meeting Abstract]
Shum, Elaine; Basturk, Olca; Klimstra, David; Tang, Laura H; Capanu, Marinela; Reidy-Lagunes, Diane L
ISI:000333166800073
ISSN: 1536-4828
CID: 2577852
Short stature in partially corrected X-linked severe combined immunodeficiency--suboptimal response to growth hormone [Case Report]
De Ravin, Suk See; Shum, Elaine; Zarember, Kol A; Rezvani, Geoffrey; Rosenfeld, Ron G; Stratakis, Constantine A; Malech, Harry L
BACKGROUND: X-linked severe combined immunodeficiency (XSCID) results from defects in the common cytokine receptor gamma chain (gamma c) required for signaling by receptors for interleukin (IL)-2, -4, -7, -9, -15, and -21. Following haploidentical bone marrow transplant without myelo-conditioning for XSCID, most patients achieve partial reconstitution often limited to T lymphocytes. Many partially corrected patients manifest extreme short stature (<5th percentile). Previous reports have implicated gamma c in growth hormone (GH) receptor signaling, thus severe growth failure in XSCID may be related to the underlying gamma c defect. AIM: To evaluate the GH/insulin-like growth factor-I (IGF-I) axis in three children with XSCID and partial immune reconstitution with profound growth failure. METHODS: The IGF-I generation test was performed by administering recombinant GH subcutaneously for 5 days, and measuring serum levels for IGF-I before GH injection, and on days 5 and 8. RESULTS: Study of the somatotropic axis revealed profoundly diminished IGF-I production following rGH challenge in all three patients. CONCLUSION: The data indicate that the GH/IGF-I axis in these partially corrected XSCID patients with severe short stature is profoundly impaired, and supports previous studies suggesting that the underlying gamma c defect may contribute to the severe growth failure in XSCID. This supports a role for defective gamma c in the extreme short stature of XSCID, and raises the possibility of recombinant IGF-I treatment to bypass this defect.
PMCID:2715294
PMID: 19189700
ISSN: 0334-018x
CID: 2443282